Health Care·Life Sciences Tools & Services·$2.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.37 | N/A | +18.32% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.37 | N/A | +18.32% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Overall, management conveyed a cautious optimism about future opportunities while recognizing current market challenges.
Management highlighted ongoing investments in innovation and product development.
They acknowledged challenges in the market but expressed confidence in long-term growth.
The earnings report shows that 10X Genomics exceeded expectations on EPS, which is a positive sign for the company. However, the stock fell by 4.61% following the announcement, likely due to the lack of revenue data and guidance. Investors may be concerned about the company's future performance without clear direction.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
STRYKER CORP
Oct 31, 2022